Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 2/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 2/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3282596 | 0.85 | PNMT (0.53) | PNMTSLC6A2SLC6A4SLC6A3TACR1 | |
| SCHEMBL5551844 | 0.85 | SLC6A2 (0.53) | PNMTSLC6A2SLC6A4SLC6A3GBA1 | |
| SCHEMBL12672176 | 0.81 | SLC6A4 (0.42) | SLC6A2SLC6A4SLC6A3DPP4LOXL2 | |
| SCHEMBL3282252 | 0.81 | NOS1 (0.43) | SLC6A2SLC6A4SLC6A3DPP4LOXL2 | |
| SCHEMBL1156843 | 0.81 | DPP4 (0.47) | SLC6A2SLC6A4SLC6A3DPP4LOXL2 | |
| SCHEMBL1157043 | 0.79 | SLC6A4 (0.60) | SLC6A2SLC6A4SLC6A3DPP4CYP1A2 | |
| Hydrochloric Acid SCHEMBL9322527 | 0.78 | SLC6A4 (0.58) | SLC6A2SLC6A4SLC6A3DPP4 | |
| Hydrochloric Acid SCHEMBL9322405 | 0.78 | SLC6A4 (0.58) | SLC6A2SLC6A4SLC6A3DPP4 | |
| SCHEMBL9306936 | 0.77 | DPP4 (0.55) | SLC6A2SLC6A4SLC6A3DPP4ALDH1A1 | |
| SCHEMBL3282306 | 0.76 | PNMT (0.56) | PNMTSLC6A2SLC6A4SLC6A3GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2249834-B1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN INC (US) | 2015-05-13 | — | — | EP | disclosed |
| EP-2249834-B1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN INC (US) | 2015-05-13 | — | — | EP | disclosed |
| EP-2242753-B1 | OXAZOLIDINE AND THIAZOLIDINE SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN INC (US) | 2015-04-08 | — | — | EP | disclosed |
| EP-2242753-B1 | OXAZOLIDINE AND THIAZOLIDINE SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN INC (US) | 2015-04-08 | — | — | EP | disclosed |
| US-8809379-B2 | Selective subtype alpha 2 adrenergic agents and methods for use thereof | ALLERGAN, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809379-B2 | Selective subtype alpha 2 adrenergic agents and methods for use thereof | ALLERGAN, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809379-B2 | Selective subtype alpha 2 adrenergic agents and methods for use thereof | ALLERGAN, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20140206701-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140206701-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140206701-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20090197898-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. | 2009-08-06 | — | — | US | disclosed |
| US-20090197898-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. | 2009-08-06 | — | — | US | disclosed |
| WO-2009091759-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. (US) | 2009-07-23 | — | — | WO | disclosed |
| WO-2009091759-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. (US) | 2009-07-23 | — | — | WO | disclosed |
| WO-2009091874-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. (US) | 2009-07-23 | — | — | WO | disclosed |
| WO-2009091760-A1 | OXAZOLIDINE AND THIAZOLIDINE SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. (US) | 2009-07-23 | — | — | WO | disclosed |
| WO-2009091760-A1 | OXAZOLIDINE AND THIAZOLIDINE SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. (US) | 2009-07-23 | — | — | WO | disclosed |
| EP-2018364-A1 | THERAPEUTIC FLUOROETHYL UREAS | Allergan, Inc. (US) | 2009-01-28 | — | — | EP | disclosed |
| WO-2007137029-A1 | THERAPEUTIC FLUOROETHYL UREAS | ALLERGAN, INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| US-20070270498-A1 | THERAPEUTIC FLUOROETHYL UREAS | ALLERGAN, INC. | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206701-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ADRB2, ADRA2C, ADRA2A | PNMT 224/4885SLC6A2 43/4885SLC6A4 238/4885 |
| US-20070270498-A1 | THERAPEUTIC FLUOROETHYL UREAS | SLC14A1, MAPT, UTS2R | PNMT 1293/4885SLC6A2 716/4885SLC6A4 1892/4885 |
| US-20090197898-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ADRB2, ADRA2C, ADRA2A | PNMT 227/4885SLC6A2 44/4885SLC6A4 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.